Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to evaluate the safety and tolerability of CSL889 in study participants, and to assess how CSL889 affects the time it takes for VOC to resolve in participants with SCD.

NCT Number	NCT06699849
Lead Sponsor	CSL Behring
Conditions	Sickle Cell Disease Vaso-occlusive Crisis
Enrollment	70 participants
Start Date	2025-08-07
Primary Completion	2027-10-22 (estimated)
Study Completion	2027-10-22 (estimated)
Updated on ClinicalTrials.gov	2026-08-14